Last $26.76 USD
Change Today -1.28 / -4.56%
Volume 142.6K
GHDX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

genomic health inc (GHDX) Snapshot

Open
$27.97
Previous Close
$28.04
Day High
$28.00
Day Low
$26.52
52 Week High
05/30/13 - $38.99
52 Week Low
02/7/14 - $25.50
Market Cap
834.5M
Average Volume 10 Days
207.6K
EPS TTM
$-0.40
Shares Outstanding
31.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENOMIC HEALTH INC (GHDX)

genomic health inc (GHDX) Related Businessweek News

View More BusinessWeek News

genomic health inc (GHDX) Details

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, facilitating physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; and Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as is used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading. Genomic Health, Inc. was founded in 2000 and is based in Redwood City, California.

684 Employees
Last Reported Date: 03/11/14
Founded in 2000

genomic health inc (GHDX) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $600.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $340.0K
Chief Operating Officer and Member of Non-Man...
Total Annual Compensation: $460.0K
Executive Vice President of Research & Develo...
Total Annual Compensation: $450.0K
Compensation as of Fiscal Year 2012.

genomic health inc (GHDX) Key Developments

Genomic Health Inc. Announces Resignation of Kathy L. Hibbs as Senior Vice President and General Counsel, Effective March 27, 2014

On March 12, 2014, Kathy L. Hibbs notified Genomic Health Inc. of her resignation as Senior Vice President and General Counsel of the company effective March 27, 2014.

Genomic Health, Inc. Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2013; the Company Provides Earnings Guidance for the Year of 2014

Genomic Health Inc. announced financial results for the fourth quarter and year ended December 31, 2013. For the quarter, the company net loss of $9.37 million, or $0.30 loss per basic share, compared to a net income of $1.96 million, or $0.06 per basic share, for the same quarter ended December 31, 2012. Total revenues for the fourth quarter ended December 31, 2013 were $68.82 million, compared to $60.43 million for the same quarter ended December 31, 2012. Net loss for the year ended December 31, 2013 was $12.76 million, or $0.42 loss per diluted share, compared to a net income of $8.25 million, or $0.26 per diluted share, for the year ended December 31, 2012. Total revenues for the year ended December 31, 2013 were $261.59 million, compared to $235.17 million for the year ended December 31, 2012. For 2014, the company expects total revenue to be in the range of $278 million to $286 million and basic net loss between $0.95 per share and $0.75 per share.

Genomic Health Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2013; Provides Earnings Guidance for the Full Year Ending December 31, 2014; Reports Unaudited Consolidated Impairments for the Fourth Quarter Ended December 31, 2013

Genomic Health Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2013. For the quarter, the company's total revenues were $68,819,000 against $60,427,000 a year ago. Loss from operations was $8,496,000 against income of $2,015,000 a year ago. Loss before income taxes was $9,247,000 against income of $2,139,000 a year ago. Net loss was $9,369,000 or $0.30 basic and diluted per share against income of $1,960,000 or $0.06 basic and diluted per share a year ago. For the year, the company's total revenues were $261,595,000 against $235,173,000 a year ago. Loss from operations was $11,832,000 against income of $8,434,000 a year ago. Loss before income taxes was $12,411,000 against income of $8,671,000 a year ago. Net loss was $12,757,000 or $0.42 basic and diluted per share against income of $8,249,000 or $0.26 diluted per share a year ago. The company provided earnings guidance for the full-year ending December 31, 2014. The company expects total revenue of $278 million to $286 million and basic net loss between $0.95 per share and $0.75 per share. The company anticipates gross margin to be approximately 82% in 2014 due to expected increases in test volumes related to increased investments in the prostate and international markets. For the quarter, the company's impairment in investments was $643,000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GHDX:US $26.76 USD -1.28

GHDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Foundation Medicine Inc $26.61 USD -1.27
LipoScience Inc $3.18 USD -0.20
NanoString Technologies Inc $17.22 USD -0.20
NeoGenomics Inc $3.38 USD -0.07
Response Genetics Inc $1.26 USD +0.01
View Industry Companies
 

Industry Analysis

GHDX

Industry Average

Valuation GHDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.3x
Price/Book 6.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENOMIC HEALTH INC, please visit www.genomichealth.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.